Aarti Pharmalabs Limited (AARTIPHARM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aarti Pharmalabs Limited (AARTIPHARM) has a cash flow conversion efficiency ratio of 0.022x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs362.80 Million ≈ $3.92 Million USD) by net assets (Rs16.58 Billion ≈ $179.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aarti Pharmalabs Limited - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Aarti Pharmalabs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Aarti Pharmalabs Limited for a breakdown of total debt and financial obligations.
Aarti Pharmalabs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aarti Pharmalabs Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BAE Systems plc
LSE:BA
|
0.265x |
|
Astra Otoparts Tbk
JK:AUTO
|
0.045x |
|
Vitesse Energy Inc
NYSE:VTS
|
0.076x |
|
Yunnan Tourism Co Ltd
SHE:002059
|
0.042x |
|
Viglacera Corp JSC
VN:VGC
|
0.209x |
|
Shenzhen Easttop Supply Chain Management Co Ltd
SHE:002889
|
-0.095x |
|
Lotte Confectionery Co Ltd
KO:280360
|
0.057x |
|
Orrstown Financial Services Inc
NASDAQ:ORRF
|
0.039x |
Annual Cash Flow Conversion Efficiency for Aarti Pharmalabs Limited (2020–2025)
The table below shows the annual cash flow conversion efficiency of Aarti Pharmalabs Limited from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Aarti Pharmalabs Limited worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs19.90 Billion ≈ $215.20 Million |
Rs3.32 Billion ≈ $35.86 Million |
0.167x | +35.32% |
| 2024-03-31 | Rs17.57 Billion ≈ $190.02 Million |
Rs2.16 Billion ≈ $23.40 Million |
0.123x | -27.03% |
| 2023-03-31 | Rs15.58 Billion ≈ $168.54 Million |
Rs2.63 Billion ≈ $28.44 Million |
0.169x | +635.36% |
| 2022-03-31 | Rs13.86 Billion ≈ $149.94 Million |
Rs-437.04 Million ≈ $-4.73 Million |
-0.032x | -- |
| 2021-03-31 | Rs2.27 Million ≈ $24.52K |
Rs0.00 ≈ $0.00 |
0.000x | -- |
| 2020-03-31 | Rs2.31 Million ≈ $25.02K |
Rs-186.75K ≈ $-2.02K |
-0.081x | -- |
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more